Foscarnet for suppression of human immunodeficiency virus replication

Antimicrob Agents Chemother. 1994 Mar;38(3):604-7. doi: 10.1128/AAC.38.3.604.

Abstract

The effect of foscarnet against human immunodeficiency virus (HIV) was evaluated in nine HIV-infected individuals; six completed 28 days of induction therapy. The overall mean increase in CD4+ lymphocytes was 64 cells per mm3. The mean decline in the HIV antigen concentration was 108 pg/ml (P = 0.03), and suppression was related to systemic foscarnet exposure by a maximum-effect pharmacodynamic model.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Bayes Theorem
  • CD4-Positive T-Lymphocytes
  • Double-Blind Method
  • Female
  • Foscarnet / administration & dosage
  • Foscarnet / pharmacokinetics
  • Foscarnet / therapeutic use*
  • HIV Antigens / analysis
  • HIV Infections / drug therapy*
  • HIV Infections / microbiology
  • Humans
  • Leukocyte Count
  • Male
  • Middle Aged
  • Virus Replication / drug effects*

Substances

  • HIV Antigens
  • Foscarnet